[China Cord Blood Corporation Receives Notice of a Transaction Regarding its 7% Senior Convertible Notes Due 2017 Held by KKR HONG KONG, China, May 4, 2015 — China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that the Company] [FORM 6-K Commission Filing Number: 001-34541 CHINA CORD BLOOD CORPORATION 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Form 20-F x Form 40-F o o o Description]

[China Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal HONG KONG, China, April 29, 2015 — China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), China’s leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that in response to the non-binding proposal letter dated] [FORM 6-K CHINA CORD BLOOD CORPORATION 48 th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Form 20-F x Form 40-F o o o Yes o No x Other Events On April 2 9 Description]

[China Cord Blood Corporation Announces Receipt of “Going Private” Proposal The Company expects that its board of directors will form a special committee of independent directors (the “Special Committee”) to consider the proposed transaction. The Company also expects that the Special Committee will retain advisors, including an independent financial advisor and legal counsel, to assist it in its work. The] [FORM 6-K Commission Filing Number: 001-34541 CHINA CORD BLOOD CORPORATION 48th Floor, Bank of China Tower 1 Garden Road Central Hong Kong S.A.R. Form 20-F x Form 40-F o o o Description]